PL2492355T3 - Receptor erytropoetyny ochronny dla tkanki (nepor) i sposoby zastosowania - Google Patents

Receptor erytropoetyny ochronny dla tkanki (nepor) i sposoby zastosowania

Info

Publication number
PL2492355T3
PL2492355T3 PL11004689T PL11004689T PL2492355T3 PL 2492355 T3 PL2492355 T3 PL 2492355T3 PL 11004689 T PL11004689 T PL 11004689T PL 11004689 T PL11004689 T PL 11004689T PL 2492355 T3 PL2492355 T3 PL 2492355T3
Authority
PL
Poland
Prior art keywords
nepor
disclosed
erythropoietin
epo
tumour
Prior art date
Application number
PL11004689T
Other languages
English (en)
Inventor
David B Jackson
Martin Stein
Hartmut Voss
Stephan Brock
Original Assignee
Molecular Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Health Gmbh filed Critical Molecular Health Gmbh
Publication of PL2492355T3 publication Critical patent/PL2492355T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/746Erythropoetin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52Assays involving cytokines
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL11004689T 2007-11-29 2008-11-28 Receptor erytropoetyny ochronny dla tkanki (nepor) i sposoby zastosowania PL2492355T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99104207P 2007-11-29 2007-11-29
EP11004689.3A EP2492355B1 (en) 2007-11-29 2008-11-28 Tissue protective erythropoietin receptor (nepor) and methods of use
EP08854346A EP2109690B9 (en) 2007-11-29 2008-11-28 Eph-b4 specific sirna for reducing epo-induced tumor cell growth during anemia treatment in cancer patients, tissue protective erythropoietin receptor (nepor) and methods of use.

Publications (1)

Publication Number Publication Date
PL2492355T3 true PL2492355T3 (pl) 2015-09-30

Family

ID=40370571

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11004689T PL2492355T3 (pl) 2007-11-29 2008-11-28 Receptor erytropoetyny ochronny dla tkanki (nepor) i sposoby zastosowania

Country Status (12)

Country Link
EP (3) EP2492355B1 (pl)
AT (1) ATE554186T1 (pl)
AU (1) AU2008328754B2 (pl)
CA (2) CA2802984C (pl)
DK (1) DK2492355T3 (pl)
ES (2) ES2542033T3 (pl)
HR (1) HRP20150733T1 (pl)
HU (1) HUE026591T2 (pl)
PL (1) PL2492355T3 (pl)
PT (1) PT2492355E (pl)
SI (1) SI2492355T1 (pl)
WO (1) WO2009068677A1 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339613B (es) 2005-08-05 2016-06-02 Araim Pharmaceuticals Inc Peptidos protectores de tejido y sus usos.
PT2056845T (pt) 2006-08-08 2017-11-17 Rheinische Friedrich-Wilhelms-Universität Bonn Estrutura e uso de oligonucleótidos com fosfato 5
US8357501B2 (en) * 2007-11-29 2013-01-22 Molecular Health Gmbh Tissue protective erythropoietin receptor (NEPOR) and methods of use
JP5689413B2 (ja) 2008-05-21 2015-03-25 ライニッシュ フリードリッヒ−ウィルヘルムズ−ユニバーシタット ボン 平滑末端を有する5’三リン酸オリゴヌクレオチドおよびその使用
US20130210030A1 (en) * 2010-07-19 2013-08-15 Cellzome Ag In vivo method for the evaluation of a compound-target interaction
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
CA2837914A1 (en) * 2011-06-15 2012-12-20 F. Hoffmann-La Roche Ag Anti-human epo receptor antibodies and methods of use
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
MX2016000448A (es) * 2013-07-17 2016-05-12 Araim Pharmaceuticals Inc Péptidos y análogos peptídicos protectores de tejido para prevenir y tratar enfermedades y trastornos asociados con daño del tejido.
US11702477B2 (en) 2015-11-06 2023-07-18 Orionis Biosciences BV Bi-functional chimeric proteins and uses thereof
CN108883180B (zh) 2016-02-05 2023-07-07 奥里尼斯生物科学私人有限公司 Clec9a结合剂及其用途
CA3023883A1 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Targeted mutant interferon-beta and uses thereof
EP3455245A2 (en) 2016-05-13 2019-03-20 Orionis Biosciences NV Therapeutic targeting of non-cellular structures
ES2917000T3 (es) 2016-10-24 2022-07-06 Orionis Biosciences BV Interferón-gamma mutante diana y usos del mismo
MX2019009255A (es) 2017-02-06 2019-11-05 Orionis Biosciences Nv Proteínas quiméricas dirigidas y sus usos.
US10906985B2 (en) 2017-02-06 2021-02-02 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof
KR102877915B1 (ko) 2018-02-05 2025-10-29 오리오니스 바이오사이언시즈 인코포레이티드 섬유아세포 결합제 및 이의 용도
WO2020198665A1 (en) 2019-03-28 2020-10-01 Orionis Biosciences, Inc. Fibroblast activation protein binding agents and use thereof
CN111175519B (zh) * 2020-01-09 2020-11-27 浙江大学 Epo在制备肝细胞癌tace疗效评估试剂中的应用
WO2022054748A1 (ja) * 2020-09-10 2022-03-17 扶桑薬品工業株式会社 エリスロポエチンシグナル伝達阻害タンパク質

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002951409A0 (en) * 2002-09-16 2002-09-26 North Western Adelaide Health Services Methods for regulating cancer
US7381410B2 (en) * 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
JP4762889B2 (ja) * 2003-03-12 2011-08-31 バスジーン セラピューティクス,インコーポレイテッド 血管形成及び腫瘍成長を阻止するための核酸化合物
US7718363B2 (en) * 2003-04-25 2010-05-18 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
JP2008514925A (ja) * 2004-09-23 2008-05-08 バスジーン セラピューティクス, インコーポレイテッド 腫瘍を検出し且つ治療するための組成物及び方法

Also Published As

Publication number Publication date
EP2109690B9 (en) 2012-10-24
EP2960341B1 (en) 2018-06-27
SI2492355T1 (sl) 2015-08-31
ES2386495T3 (es) 2012-08-21
EP2492355A1 (en) 2012-08-29
AU2008328754B2 (en) 2015-04-16
HRP20150733T1 (hr) 2015-08-14
EP2109690B1 (en) 2012-04-18
DK2492355T3 (da) 2015-07-13
EP2492355B1 (en) 2015-04-08
EP2960341A1 (en) 2015-12-30
ATE554186T1 (de) 2012-05-15
PT2492355E (pt) 2015-09-10
AU2008328754A1 (en) 2009-06-04
CA2706994A1 (en) 2009-06-04
ES2542033T3 (es) 2015-07-29
CA2802984C (en) 2016-04-12
WO2009068677A1 (en) 2009-06-04
CA2706994C (en) 2013-03-12
CA2802984A1 (en) 2009-06-04
HUE026591T2 (hu) 2016-06-28
EP2109690A1 (en) 2009-10-21

Similar Documents

Publication Publication Date Title
SI2492355T1 (sl) Tkivno protektivni eritropoetinski receptor (nepor) in postopki uporabe
Zhu et al. MicroRNA-21 regulates hTERT via PTEN in hypertrophic scar fibroblasts
Li et al. Expression of long non-coding RNA DLX6-AS1 in lung adenocarcinoma
EP2531598A4 (en) WHSC1 AND WHSC1L1 FOR TARGET GENES TO CANCER THERAPY AND DIAGNOSIS
Buess et al. Tumor-Endothelial interaction links the CD44+/CD24-phenotype with poor prognosis in early-stage breast cancer
MX2022006075A (es) Antagonistas de union a pd-l1 y usos de los mismos para el tratamiento de cancer.
Zhang et al. CtBP2 could promote prostate cancer cell proliferation through c-Myc signaling
WO2005100998A3 (en) Membrane markers for use in cancer diagnosis and therapy
EA200802242A1 (ru) Способ определения того, будет или не будет пациент респондером на иммунотерапию
TW200642695A (en) Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs)
Ohta et al. Human umbilical cord matrix mesenchymal stem cells suppress the growth of breast cancer by expression of tumor suppressor genes
Zhang et al. Upregulation of KIN17 is associated with non-small cell lung cancer invasiveness
MXPA05014220A (es) Genes regulados en cancer ovarico como objetivos de pronostico y terapeuticos.
Wu et al. LncRNA AWPPH accelerates the progression of non-small cell lung cancer by sponging miRNA-204 to upregulate CDK6.
Abdullah et al. Proliferation rate of stem cells derived from human dental pulp and identification of differentially expressed genes
Pereira et al. miRNAs: important targets for oral cancer pain research
Luo et al. TM4SF19-AS1 facilitates the proliferation of lung squamous cell carcinoma by recruiting WDR5 to mediate TM4SF19
Wada et al. Effect of plasma-activated medium on the decrease of tumorigenic population in lymphoma
Coelho et al. Circulating Ang-2 mRNA expression levels: looking ahead to a new prognostic factor for NSCLC
WO2005083086A3 (en) Epha4 as therapeutic target of prc and pdaca
Wu et al. Protein phosphatase 2A regulatory subunit B56β modulates erythroid differentiation
Liang et al. lncRNA NR2F2-AS1 inhibits the methylation of miR-494 to regulate oral squamous cell carcinoma cell proliferation
Liu et al. Interaction between stromal cells and tumor cells promotes GCB-DLBCL cell survival via the CD40/RANK-KDM6B-NF-κB axis
WO2017053763A3 (en) ANDROGEN RECEPTOR VARIANT 7 AS A BIOMARKER FOR TREATMENT SELECTION IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (mCRPC)
Kaira et al. Expression of excision repair cross-complementation group 1, breast cancer susceptibility 1, and β III-tubulin in thymic epithelial tumors